GlobeNewswire·Oct 30, 2026, 7:00 AM ET

Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization

GUTS

Fractyl Health announced new U.S. patent additions strengthening the intellectual property foundation for Revita ahead of a planned FDA De Novo submission for post-GLP-1 weight maintenance.
The company's IP portfolio now includes 39 granted U.S. patents, approximately 40 pending U.S. applications, and more than 50 issued international patents.
U.S. Patent No. 12,740,821 covers specific design features of the Revita single-use catheter, with patent protection extending to November 28, 2042.
The USPTO issued a Notice of Allowance for Patent Application No. 18/988,800, which claims a thermal dosing method controlling heated & cooling fluids to regulate the thermal dose delivered to the duodenal lining.
U.S. Patent No. 12,471,979 includes independent treatment-method claims for duodenal tissue that are not limited to any specific energy modality, covering procedural steps like positioning & delivering energy.
These developments complement U.S. Patent No. 12,690,909, issued in July 2026, which covers the heater design for the Revita console.
Patent milestones build on positive six-month results from the REMAIN-1 Pivotal Cohort & market research showing patient interest in a one-time procedure for weight maintenance after GLP-1 therapy.
Revita is an endoscopic procedural therapy designed to remodel the duodenal lining to enable durable weight maintenance following GLP-1 discontinuation.
Revita holds FDA Breakthrough Device Designation for weight maintenance in people with obesity who discontinue GLP-1 therapies.